The Impact of Sophisticated Data Analysis on the Drug Discovery Process 2 Heading Sub Head

There should be no question that a better understanding of biological and chemical phenomena at the molecular level will greatly improve the drug discovery process, resulting in a larger number of more efficient drugs with less adverse effects, and all at lower total cost. There should also be no question that modern highthroughput technologies such as microarrays and mass spectrometry are key to this process in obtaining insight at the molecular level – providing it will be possible to interpret the ever-increasing quantities of experimental data generated with such technologies in a meaningful and efficient way. However, the state of processing such experimental data in the drug discovery industry is in its infancy and lots of resources and money is wasted, in particular with regards to the data analysis and data management processes. The industry clearly needs to increase R/D-IT investments and take advantage of costreduction potential from outsourcing to streamline and optimise their data analysis and data management processes in order to get a positive return on investment (ROI) in high-throughput technologies.

[1]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Anders Wallqvist,et al.  Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. , 2002, Molecular cancer therapeutics.

[3]  N. Brunner,et al.  Genome-wide mRNA profiling: impact on compound evaluation and target identification in anti-bacterial research , 2002 .

[4]  Andrea Califano,et al.  Analysis of Gene Expression Microarrays for Phenotype Classification , 2000, ISMB.

[5]  Michael Y. Galperin,et al.  Searching for drug targets in microbial genomes. , 1999, Current opinion in biotechnology.

[6]  Paul Workman,et al.  Translating basic cancer research into new cancer therapeutics. , 2002, Trends in molecular medicine.

[7]  K. Morgan.  Gene expression analysis reveals chemical-specific profiles. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  W Keck,et al.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. , 2001, Genome research.

[9]  D. Stone,et al.  Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[11]  K. Thompson,et al.  Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. , 2004, Environmental health perspectives.

[12]  Christoph Freiberg,et al.  Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. , 2003, Genome research.

[13]  R. Illingworth,et al.  The impact of genomics and related technologies on the search for new antibiotics , 2002, Journal of applied microbiology.

[14]  Mark W. Craven,et al.  Identification of toxicologically predictive gene sets using cDNA microarrays. , 2001, Molecular pharmacology.

[15]  Stephen H. Friend,et al.  Toxicogenomics and drug discovery: will new technologies help us produce better drugs? , 2002, Nature Reviews Drug Discovery.

[16]  Christoph Schaab,et al.  Panel of Bacillus subtilis Reporter Strains Indicative of Various Modes of Action , 2004, Antimicrobial Agents and Chemotherapy.

[17]  Christoph Freiberg,et al.  Novel computational methods in anti-microbial target identification , 2001 .

[18]  R G Ulrich,et al.  Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.

[19]  P. Workman.  The impact of genomic and proteomic technologies on the development of new cancer drugs , 2002 .

[20]  Turning quantity into quality: novel quality assurance strategies for data produced by high-throughput genomics technologies , 2002 .